This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2013 Remove Pharmacology Remove Side effects
article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

MAY 2, 2023

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

Side effects 86
Side effects Prescription Healthcare Healthcare 86
article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

OCTOBER 10, 2022

Since the publication of the fifth Diagnostic and Statistical Manual of Mental Disorders in 2013, both conditions are grouped under the term FSIAD, which includes reduced arousal and interest. One Phase II trial was completed back in 2013, as per ClinicalTrials.gov. Neither Addyi nor Vyleesi is approved by the EMA.

Pharmacology 59
Pharmacology Side effects FDA Safety 59
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024